The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Challenges with managing the high rates of infections seen in patients with AML
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges of approaching the high risk of infections seen in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Dr Žučenka highlights factors influencing infection risk in these patients, commenting on the importance of antifungal, antibacterial, and antiviral prophylaxis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Astellas, Pfizer, Novartis, Janssen
Honoraria: Abbvie, Astellas, Novartis, Janssen
Travel Expenses: Abbvie, Novartis, Janssen, Takeda
